



The Illinois Medical Bulletin



The Association Between Low Serum Testosterone and the Risk of Type 2 Diabetes and Metabolic Syndrome in Men: A Review of the Epidemiological Evidence

¹A. Bardwell, ²A. Barnes

^{1,2} University of Illinois College of Medicine

Corresponding Email : drbardwell29383747@gmail.com

Article History :

Received date : 2024/10/12
Revised date : 2024/11/28
Accepted date : 2024/12/09
Published date : 2025/01/13



Copyright: © by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (BY NC) license (<https://creativecommons.org/licenses/by-nc/4.0/>).

ABSTRACT

Introduction: Declining serum testosterone levels are a common physiological change in aging men. Concurrently, the prevalence of the metabolic syndrome and type 2 diabetes has reached epidemic proportions. This has prompted significant investigation into the potential role of sex hormones in metabolic health.

Literature Review: A review of the pivotal epidemiological literature reveals a strong, consistent, and independent inverse association between serum testosterone concentrations and adverse metabolic risk in men. Large-scale cross-sectional studies have consistently demonstrated that men with lower testosterone levels have a significantly higher prevalence of the metabolic syndrome. More powerfully, major prospective cohort studies have established that low baseline testosterone is a robust predictor of the future development of type 2 diabetes, even after adjusting for traditional risk factors, including obesity. The biological plausibility for this link is strong, with evidence showing that low testosterone promotes an increase in visceral adiposity and a decrease in muscle mass, which are key drivers of insulin resistance.

The relationship is now considered to be bidirectional, with obesity and inflammation also contributing to the suppression of testosterone production.

Conclusion: The body of evidence reviewed confirms that low serum testosterone in men is not merely a marker of aging but is a significant and independent predictor of the metabolic syndrome and type 2 diabetes. This research has been fundamental in repositioning testosterone as a key metabolic hormone.

Keywords: Testosterone, Hypogonadism, Type 2 Diabetes, Metabolic Syndrome, Insulin Resistance, Epidemiology.

INTRODUCTION

The metabolic syndrome is a clustering of cardiometabolic risk factors—namely central obesity, insulin resistance, atherogenic dyslipidemia, and elevated blood pressure—that collectively and synergistically increase the risk of developing type 2 diabetes and atherosclerotic cardiovascular disease. In parallel with the global obesity epidemic, the prevalence of this syndrome has risen to affect a large proportion of the adult population. While lifestyle and diet are central to its development, there is growing interest in identifying other modifiable biological factors that contribute to this adverse metabolic state.

Testosterone is the principal male androgen, essential for the development and maintenance of reproductive tissues and secondary sexual characteristics. It is also increasingly recognized as having profound effects on body composition, glucose homeostasis, and lipid metabolism. Given that testosterone levels naturally decline with age in men, and that this decline coincides with an age-related increase in metabolic disease, a crucial clinical question arose: is there a causal link between low testosterone and metabolic dysfunction? This literature review will synthesise the pivotal epidemiological evidence that established the strong association between low serum testosterone levels and the risk for the metabolic syndrome and type 2 diabetes in men.

LITERATURE REVIEW

The scientific case linking low testosterone to adverse metabolic health was built upon a strong foundation of consistent findings from large-scale cross-sectional and prospective observational studies.

Numerous large, population-based cross-sectional studies provided the initial, powerful evidence of an association. These studies, which assessed hormonal and metabolic parameters at a single point in time in thousands of men, consistently found a strong inverse correlation between serum testosterone concentrations and the prevalence of the metabolic syndrome. Men in the lowest quartiles or quintiles of testosterone distribution were several times more likely to meet the diagnostic criteria for the metabolic syndrome than men in the highest testosterone quartiles. This association remained significant even after adjusting for potential confounding variables like age and lifestyle factors (Muller et al., 2005).

While cross-sectional data establish an association, prospective cohort studies are required to determine if low testosterone is a predictor of future disease. Several major, long-term prospective studies provided definitive evidence in this regard. These studies enrolled large cohorts of initially non-diabetic men, measured their baseline hormone levels, and followed them for many years to track the incidence of new-onset type 2 diabetes. The results were remarkably consistent across different populations: men with lower baseline levels of total and/or free testosterone had a significantly higher risk of developing type 2 diabetes during the follow-up period. This increased risk was independent of baseline obesity and other conventional risk factors, establishing low testosterone as an independent predictor of future diabetes (Laaksonen et al., 2004; Oh et al., 2002).

The biological plausibility of this relationship is strong and is primarily linked to testosterone's effects on body composition and insulin sensitivity. Testosterone has a known anabolic effect, promoting the development of lean muscle mass, while having an inverse relationship with fat mass, particularly visceral adipose tissue. A decline in testosterone promotes the accumulation of visceral fat, a key driver of insulin resistance. Indeed, studies have directly demonstrated that lower testosterone levels are independently correlated with higher degrees of insulin resistance, as measured by methods like the homeostatic model assessment (HOMA-IR). Experimental studies in healthy men further confirmed this, showing that medically induced hypogonadism rapidly leads to increased fat mass and the development of insulin resistance, providing direct evidence for a causal link (Pitteloud et al., 2005).

The relationship is now understood to be a complex, bidirectional "vicious cycle." While low testosterone promotes fat gain and insulin resistance, the reverse is also true. Obesity, particularly central obesity, and its associated state of low-grade systemic inflammation are

known to suppress the hypothalamic-pituitary-gonadal axis, leading to reduced testosterone production. This creates a self-perpetuating cycle where low testosterone leads to metabolic dysfunction, which in turn further lowers testosterone levels (Kapoor et al., 2006).

CONCLUSION

The pivotal literature on the metabolic role of testosterone in men provides a clear and consistent conclusion. A substantial body of high-quality observational evidence, from both cross-sectional and prospective cohort studies, has unequivocally established a strong, independent, and inverse association between serum testosterone levels and the risk of both the metabolic syndrome and incident type 2 diabetes.

This relationship is supported by a strong mechanistic rationale centered on the profound influence of testosterone on body composition and insulin sensitivity. The research has successfully reframed our understanding of testosterone, moving it beyond its classical role as a reproductive hormone to recognize it as a key regulator of metabolic health in men. This body of work has established low testosterone as a critical biomarker and contributor to cardiometabolic risk, prompting a new focus on the metabolic consequences of male hypogonadism.

REFERENCES

- Kapoor, D., Goodwin, E., Channer, K.S. and Jones, T.H. (2006) 'Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes', *European Journal of Endocrinology*, 154(6), pp. 899-906.
- Laaksonen, D.E., Niskanen, L., Punnonen, K., Nyyssönen, K., Tuomainen, T.P., Valkonen, V.P., Salonen, R. and Salonen, J.T. (2004) 'Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men', *Diabetes Care*, 27(5), pp. 1036-1041.
- Muller, M., Grobbee, D.E., den Tonkelaar, I., Lamberts, S.W. and van der Schouw, Y.T. (2005) 'Endogenous sex hormones and the risk of type 2 diabetes in older men', *Diabetes*, 54(11), pp. 3042-3045.

Oh, J.Y., Barrett-Connor, E., Wedick, N.M. and Wingard, D.L. (2002) 'Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study', *Diabetes Care*, 25(1), pp. 55-60.

Pitteloud, N., Mootha, V.K., Dwyer, A.A., Hardin, M., Lee, H., Eriksson, K.F., Tripathy, D., Yialamas, M., Groop, L., Elahi, D. and Hayes, F.J. (2005) 'Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men', *Diabetes Care*, 28(7), pp. 1636-1642.